This paper compared the detection of mutations in whole genome amplified (WGA) DNA in fingerstick capillary and venous blood with DNA in matched unamplified venous blood. In select specimens, the cell-free DNA mutational profile was compared to that in previously analyzed tumor specimens. The authors also optimized the WGA methodology.
Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood.
Gyanchandani R, Kvam E, Heller R, Finehout E, Smith N, Kota K, Nelson JR, Griffin W, Puhalla S, Brufsky AM, Davidson NE, Lee AV
Purpose
Conclusion
For one of the three venous specimens found to harbor mutations, prior analysis of the tumor found that it harbored one of the mutations investigated (PIK3CA-N345K). The PIK3CA-H1047R mutation was identified in the prior analysis of the tumor in an additional specimen for which no mutations were found in the venous specimen. Whole genome via rolling-circle amplification (WG-RCA) was able to increase the concentration of cell-free DNA (cfDNA) from both venous and capillary specimens by >1000-fold with a greater increase observed in capillary specimens, but MDA amplification resulted in allelic imbalance and poorer coverage. Using droplet-digital PCR (ddPCR), there was 100% concordance in genotypes among matched WG-RCA amplified and unamplified venous specimens and WG-RCA amplified fingerstick specimens but more variability in the mutant allele fraction was observed for a trace mutation in the ddPCR assay after amplification. The allelic frequencies obtained by ddPCR in amplified specimens were similar to those observed in unamplified venous specimens using NGS.
Studies (1)
Purpose
This study compared the detection of mutations in whole genome amplified (WGA) DNA in fingerstick capillary and venous blood with DNA in matched unamplified venous blood. In select specimens, the cell-free DNA mutational profile was compared to that in previously analyzed tumor specimens. The authors also optimized the WGA methodology. Venous blood was obtained from seven healthy patients with ER-positive breast cancer into Streck Cell-Free DNA Blood Tubes and fingerstick blood was obtained simultaneously from the same seven patients by fingerstick into MicroSafe Blood Collection Tubes and then immediately spotted onto the point-of-care paper-based PlasmaClip. Plasma and buffy coast were obtained from the venous blood by centrifugation at 1600 x g for 10 minutes at 4°C and plasma was then further purified by centrifugation at 1600 x g for 10 minutes at 4°C and then at 16,000 x g for 10 minutes at 4°C. Plasma and buffy coat were stored at -80°C until DNA extraction. Genomic DNA was extracted from the buffy coat using DNeasy Blood & Tissue Kit and quantified by Qubit dsDNA BR assay kit. cfDNA was extracted from thawed plasma using the QIAamp Circulating Nucleic Acid Kit without the carrier RNA and quantified using the PicoGreen dsDNA Kit. After blood was allowed to air-dry on the PlasmaClip for 5-10 min, specimens were sealed in screw-top tubes with dessicant at room temperature and then shipped/stored at ambient temperature for 6-19 days before cfDNA extraction using a modification of the DNA Extractor SP kit. All of the fingerstick cfDNA and 15% of the venipuncture cfDNA was amplified by whole genome rolling circle amplification, purified with SureClean Plus, and quantified using Quant-iT dsDNA Broad-Range Assay Kit. A single specimen was amplified using both WG-RCA and multiple displacement amplification. MammaSeq breast cancer panel libraries were prepared using Ion AmpliSeq Library Kit 2.0 and sequenced on the Ion Proton and Ion Torrent Personal Genome Machine. PIK3CA (H1047R), PIK3CA (E545K), KRAS (G12D), PIK3CA-N345K, ESR1-D538G, and ESR1-Y537C were amplified by ddPCR. Importantly, prior sequencing data (7 months and 12 months) was available for tumor specimens collected from two of the patients with successful venous blood specimens.
Summary of Findings
Extraction yielded 11-152 ng/mL cfDNA from venous blood but six specimens yielded <30 ng/mL. Of the six venous specimens that provided enough cfDNA for sequencing, three harbored circulating mutations. For only one of these of these three patients, prior analysis of the tumor found that it harbored one of the mutations investigated(PIK3CA-N345K). The PIK3CA-H1047R mutation was found in the prior analysis of the tumor in an additional specimen for which no mutations were found in circulating blood. WG-RCA was able to increase the concentration of cfDNA from both venous and capillary specimens by >1000-fold with a greater increase observed in capillary specimens. In a single specimen, MDA amplification resulted in allelic imbalance and poorer coverage relative the WG-RCA. The authors found that fragmentation was best achieved by boiling for 5 min (rather than boiling for 0.5, 1, 2, 3, 4, 7.5, 10, 15, or 30 min or using g-TUBE centrifugal shear) and could be used for an input of 10-100 ng without affecting the fractional abundance. Using ddPCR, there was 100% concordance in genotypes among matched WG-RCA amplified and unamplified venous specimens and WG-RCA amplified fingerstick specimens but more variability in the mutant allele fraction was observed for a trace mutation in the ddPCR assay after amplification. The allelic frequencies obtained by ddPCR in amplified specimens were also similar to those observed in unamplified venous specimens using NGS.
Biospecimens
FluidBloodFluidPlasmaPreservation Types
FrozenStreck/BCTOther PreservativeDiagnoses
NeoplasticCarcinomaPlatforms
DNANext generation sequencingDNADigital PCRDNAFluorometryDNAWhole genome amplificationPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Method of fluid acquisition Finger/heel prick samplingVenipunctureBiospecimen Acquisition Type of collection container/solution PlasmaClipStreck BCTWhole genome amplification Specific Nucleic acid amplification MDAWG-RCAWhole genome amplification Specific Template/input amount 10 ng100 ng75 ngDigital PCR Specific Technology platform MammaSeq NGSDigital PCR Specific Template modification Unamplified venous cfDNAWG-MDA venous cfDNAWG-RCA capillary cfDNAWG-RCA venous cfDNA